ACADIA Pharmaceuticals (NASDAQ:ACAD) : The most positive equity analysts on ACADIA Pharmaceuticals (NASDAQ:ACAD) expects the shares to touch $55, whereas, the least positive believes that the stock will trade at $35 in the short term. The company is covered by 9 Wall Street Brokerage Firms. The average price target for shares are $46.44 with an expected fluctuation of $6.65 from the mean.
Other Equity analysts have also commented on the company shares. Equity Analysts at the Brokerage Firm, Leerink Swann, downgrades their rating on the shares of ACADIA Pharmaceuticals (NASDAQ:ACAD). Leerink Swann has a Market Perform rating on the shares. Previously, the analysts had a Outperform rating on the shares. The rating by the firm was issued on May 3, 2016.
ACADIA Pharmaceuticals (NASDAQ:ACAD): The stock was completely flat for the day, closing at $33.50 on Thursday. The flat closing masks the intraday volatility in the stock. After opening at $33.50, the stock touched an intraday high of $33.96 and a low of $32.52. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $33.50. The total trading volume on Thursday was 2,610,930.
The company shares have dropped -21.66% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $51.99 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $34.44 and the 200 Day Moving Average price is recorded at $28.51. On the companys insider trading activities, The Securities and Exchange Commission has divulged that Baity Glenn, (EVP AND GC) of Acadia Pharmaceuticals Inc, had unloaded 7,000 shares at an average price of $20.8 in a transaction dated on March 2, 2016. The total value of the transaction was worth $145,600.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Companys drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinsons disease psychosis, Alzheimers disease psychosis, Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin, is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan, has discovered and engaged in the development of small-molecule product candidates, such as alpha adrenergic agonists and muscarinic receptors.